Joint working executive summary

Managing patients with stable prostate cancer in the community setting

Project description

This joint working project was designed to review and improve urology care pathways within Barking and Dagenham CCG, with the objective being to enable patients with stable prostate cancer to be treated closer to home with more personalised and flexible care facilitating a return to normal life. The project ran between September 2011 and December 2011.

Organisations involved

Ipsen Ltd and Barking and Dagenham CCG

Project process

The project focused on a specific part of the care pathway for prostate cancer patients. Patients with stable prostate cancer currently undergoing Prostate Specific Antigen (PSA) testing every 6 to 12 months within secondary care. A clinical definition for patients with stable prostate cancer, who are eligible for management within the new discharge pathway was developed and agreed by the urology department at Redbridge University Hospitals NHS Trust (BHRUT). A clinical audit was then undertaken by administrative and clinical members of the Barking Havering and BHRUT urology department to identify the patients who were appropriate for follow-up care in the community. Discharge guidelines and a care pathway for the management of patients with stable prostate cancer in a community setting were developed with the secondary care stakeholders at BHRUT who approved them for use. The next stage was to implement the discharge pathway within the CCG. A CCG board paper was written by the steering committee to support the implementation of the pathway that was developed, however it was never reviewed due to the NHS changes which resulted in this project becoming a low priority to the CCG.


For the patients:

  • Delivery of follow-up care closer to home
  • Reduction in appointment burden through coordination of combined treatment, PSA testing/ monitoring and follow up assessments in primary care

For the NHS:

  • Providing more efficient services and managing demand as a consequence of the
    review and improvement of urology care pathways
  • Reduction in follow-up referrals into secondary care in relation to the management of stable prostate cancer resulting in a reduction in tariff costs
  • Optimisation of pharmaceutical efficiency and practice time in administering LHRH injections, PSA testing and follow-up
  • Improved communication between primary and secondary care
  • Appropriate shift in activity from secondary to primary care

For Ipsen:

  • Partnering in a transparent and ethical way with an emerging CCG to share with other NHS organisations and to help add value to the Ipsen service offering
  • Gaining a better understanding of NHS systems and approaches through:
    • involvement in developing innovative approaches to patient care
    • involvement in care pathway development.